等待開盤 10-24 09:30:00 美东时间
+0.020
+0.08%
精彩内容 抗体类药物是目前现代生物医药领域的重要疗法。米内网数据显示,2025H1中国三大终端六大市场抗体类药物销售额首破900亿元;公立医疗机构品牌TOP2...
10-22 16:39
-- Management to host webcast and conference call on Friday, October 24, 2025 --Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and
10-15 00:47
Arcus Biosciences reports casdatifan monotherapy data in renal cancer, showing a 35% response rate and median progression-free survival not yet reached.
10-07 02:23
Regency Centers Corporation will announce its third quarter 2025 earnings results on October 28, 2025, after the market closes. The earnings release and supplementary information will be available on the investor relations section of its website. The company will host an earnings conference call on October 29, 2025, at 11:00 a.m. ET. Participants can dial into the call at 877-407-0789 or 201-689-8562. A webcast will be available on the Investor R...
09-30 20:15
(来源:抗体圈) 2020年前后,同种异体CAR-T(AlloCAR-T)疗法风头无两。作为传统自体CAR-T的升级方向,它承诺摆脱“一人一药”的定制化...
09-22 18:46
证券之星消息,截至2025年9月15日收盘,新吉奥房车(00805.HK)报收于1.17港元,与上一交易日持平,成交量8.6万股,成交额10.13万港元。
09-15 18:12
Exelixis (NASDAQ:EXEL) is shutting down a facility in King of Prussia, Pa., to focus its operations at its headquarters in Alameda, Calif. As a result, 130 employees will be laid off, according to Fie...
09-04 22:19
Regency Centers Corporation announced that its management team will present at the BofA Securities 2025 Global Real Estate Conference on September 9, 2025, at 2:15 p.m. ET. The presentation will be available via webcast, with a replay accessible on the Company’s website within 24 hours. Regency Centers, a leading owner, operator, and developer of shopping centers, is an S&P 500 REIT focused on properties in suburban areas with strong demographics...
09-02 12:15
FDA sent a second CRL to Telix, delaying its kidney cancer PET drug. Analysts weigh pricing pressure, and growth opportunities.
08-29 01:08
NEW HAVEN, Conn., Aug. 28, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalb...
08-28 19:30